Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-26EMA Authorised: Kisqali (ribociclib succinate) — Novartis Europharm Limited
The European Medicines Agency authorised Kisqali (ribociclib succinate) for breast cancer in the EU.
-
EMA approval · 2026-01-23EMA Authorised: Ontruzant (trastuzumab) — Samsung Bioepis NL B.V.
EMA authorised Ontruzant (trastuzumab) from Samsung Bioepis NL B.V., a biosimilar to trastuzumab for breast and gastric cancers.
-
EMA approval · 2026-01-21EMA Authorised: Abraxane (paclitaxel) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Abraxane (paclitaxel) by Bristol-Myers Squibb Pharma EEIG for breast cancer, pancreatic cancer, and non-small cell lung cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-19EMA Authorised: Zercepac (trastuzumab) — Accord Healthcare S.L.U.
The EMA authorised Zercepac, a trastuzumab biosimilar from Accord Healthcare S.L.U., for breast cancer and stomach cancer.
-
FDA approval · 2026-01-14FDA Approved: TOREMIFENE CITRATE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for toremifene citrate from Rising Pharma Holdings, Inc., under an Abbreviated New Drug Application …
-
EMA approval · 2026-01-06EMA Authorised: Itovebi (inavolisib) — Roche Registration GmbH
EMA authorised Itovebi (inavolisib) by Roche Registration GmbH for breast cancer.
-
EMA approval · 2025-11-25EMA Authorised: Tukysa (tucatinib) — Pfizer Europe MA EEIG
The EMA has authorised Tukysa (tucatinib) for use in the European Union for metastatic breast cancer, with Pfizer Europe MA EEIG as the mark…
-
EMA approval · 2025-11-20EMA Authorised: Afinitor (everolimus) — Novartis Europharm Limited
EMA authorised Afinitor (everolimus) for renal cell carcinoma, breast cancer and pancreatic neoplasms. The marketing authorisation holder is…
-
FDA approval · 2025-11-12FDA Tentative Approval: FLUOROURACIL — Supplemental Application (Gland Pharma Limited)
FDA Tentative Approval for Fluorouracil from Gland Pharma Limited under an ANDA, indicating a pathway to U.S. market subject to regulatory t…
-
EMA approval · 2025-11-04EMA Authorised: Truqap (capivasertib) — AstraZeneca AB
The European Medicines Agency authorised Truqap (capivasertib) for breast cancer. Marketing authorization holder: AstraZeneca AB (decision d…
-
EMA approval · 2025-11-04EMA Authorised: Piqray (alpelisib) — Novartis Europharm Limited
The European Medicines Agency authorised Piqray (alpelisib) by Novartis Europharm Limited for breast cancer, with decision dated 02 October …
-
EMA approval · 2025-10-30EMA Authorised: Perjeta (pertuzumab) — Roche Registration GmbH
The EMA authorised Perjeta (pertuzumab) for breast cancer in the European Union, with the decision dated 04/09/2025.
-
EMA approval · 2025-10-28EMA Authorised: Phesgo (pertuzumab;trastuzumab) — Roche Registration GmbH
The European Medicines Agency has authorised Phesgo, a fixed-dose subcutaneous combination of pertuzumab and trastuzumab, for breast cancer …
-
FDA approval · 2025-10-24FDA Approved: ANASTROZOLE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for ANASTROZOLE from Aurobindo Pharma Limited, authorizing a new generic version of the aromatas…
-
EMA approval · 2025-10-20EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH
EMA authorised Herwenda, a trastuzumab biosimilar by Sandoz GmbH, for certain HER2-positive cancers. Approved indications include breast can…
-
EMA approval · 2025-10-09EMA Authorised: Fulvestrant Mylan (fulvestrant) — Mylan Pharmaceuticals Limited
The European Medicines Agency authorised Fulvestrant Mylan, a generic fulvestrant product, for the treatment of breast cancer.
-
FDA approval · 2025-10-01FDA Approved: LETROZOLE — Supplemental Application (Accord Healthcare, Inc.)
The FDA approved a supplemental application for letrozole by Accord Healthcare, Inc., resulting in updated labeling for the product.
-
FDA approval · 2025-09-25FDA Approved: INLURIYO — Original Application (Eli Lilly and Company)
FDA approved INLURIYO (imlunestrant) from Eli Lilly in an original NDA, an oral selective estrogen receptor degrader for estrogen receptor–p…
-
FDA approval · 2025-09-23FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for leuprolide acetate (generic) submitted by Eugia US LLC under an ANDA.
-
FDA approval · 2025-09-23FDA Approved: TRIPTODUR — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TRIPTODUR (triptorelin) from Azurity Pharmaceuticals, Inc.
-
FDA approval · 2025-09-23FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Leuprolide acetate from Amneal Pharmaceuticals LLC, granting approval for a generic version of t…
-
FDA approval · 2025-09-19FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals Inc)
FDA approved a supplemental application for Leuprolide acetate from Meitheal Pharmaceuticals Inc.
-
FDA approval · 2025-09-17FDA Approved: FULVESTRANT — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Fulvestrant filed by Hikma Pharmaceuticals USA Inc. This action formalizes an updated regula…